The invention relates to genetically encoded fusion proteins comprised of a capture component that binds a target with high affinity and a peptide polymer, such as elastin-like polypeptides, that display phase behavior and can be used for purification. The invention further relates to methods for optimizing capture fusion proteins for individual biologic targets such that phase separation occurs under desirable conditions, such as at room temperature, lower concentrations of salt, and/or at suitable pH ranges and optimized capture domains and polypeptides with phase behavior that have been identified by the optimization methods.

The invention relates to genetically encoded fusion proteins comprised of a capture component that binds a target with high affinity and a peptide polymer, such as elastin-like polypeptides, that display phase behavior and can be used for purification. The invention further relates to methods for optimizing capture fusion proteins for individual biologic targets such that phase separation occurs under desirable conditions, such as at room temperature, lower concentrations of salt, and/or at suitable pH ranges and optimized capture domains and polypeptides with phase behavior that have been identified by the optimization methods.

The invention relates to antibody conjugates (e.g., a bispecific antibody), drug and nanoparticle compositions and methods and compositions for generating them. This invention further relates to methods of using these compositions for imaging, diagnosing or treating a disease.

The present invention relates to the technical field of protein biological functions, in particular to a polypeptide, a fusion type multimeric protein and use thereof, the polypeptide is selected from: (1), a polypeptide having a substitution mutation in at least one position selected from the group consisting of positions 16, 25, 29, 49 and 58, as compared with a natural C structural domain of a protein A as shown in SEQ ID NO.1; wherein, the position 16 is subjected to a substitution mutation into leucine or valine; the position 25 is subjected to a substitution mutation into lysine, arginine, histidine or tryptophan; the position 29 is subjected to a substitution mutation into alanine, leucine or threonine; the position 49 is subjected to a substitution mutation into arginine or histidine; and the position 58 is subjected to a substitution mutation into glycine, isoleucine or alanine; or (2) a polypeptide having at least 80% of sequence identity to the polypeptide in (1) and retaining substitution mutation in at least one position selected from the group consisting of positions 16, 25, 29, 49 and 58; the polypeptide has high alkali tolerance and high loading capacity.

The present invention relates to novel proteins that specifically bind to the ferritin. The novel proteins of the present invention are advanced and powerful tools because they allow precise purification methods of ferritin, for example via affinity chromatography. Further, the binding protein for ferritin is useful for methods to analyze the presence of ferritin.

The present invention provides polypeptides capable of targeting antigens, such as neoantigens, to particular immune cells, and associated therapeutic methods. In particular embodiments, the polypeptides are antibodies or antibody-based polypeptides.

The present invention relates to agents capable of inducing vascularisation. The disclosure also relates to treatment of diseases, such as cardiovascular diseases using said agents.

Fusion polypeptides including at least one Fc binding domain linked to at least one integrin binding domain are provided. In some embodiments, the at least one Fc binding domain is one or more Fc binding domains from Protein A, Protein G, or Protein Z and the at least one integrin binding domain comprises one or more fibronectin type III domains (for example repeats 12-14 of fibronectin type III domains and optionally the connecting segment of fibronectin). Protein complexes including the polypeptide and one or more antibodies are also provided. Methods of using the polypeptide and/or polypeptide:antibody complex are provided, including treating a subject with a tumor, inducing an immune response to a tumor, and/or targeting an antibody to a tumor cell.

The present invention relates to the field of protein engineering and purification and relates in particular to novel polypeptides having a triple-helical structure and lacking binding affinity for the Fc domain of immunoglobulin. The invention further relates to uses of the novel non-Fc binding polypeptides in technical applications such as affinity chromatography, as well as in therapy and diagnostics. In addition, the present invention relates to a method of reducing the binding affinity of a polypeptide having a triple-helical structure for the Fc domain of immunoglobulin.

Provided herein are fusion proteins comprising transposase domains and DNA targeting domains. In particular, the DNA targeting domains may be targeted to the lipoprotein A (LPA) gene. Also provided are methods of making the transposase domains and fusion proteins, cells that are modified using the fusion proteins provided herein and methods of treatment using such cells.